Bioprocessing Network: BioProNET

生物制品是通过细胞过程制造的复杂分子，这种生物制品对英国和全球都具有重大的经济和社会价值。生物制品包括一系列治疗性(如胰岛素等生物制药分子和赫赛汀等抗体)和非治疗性(如诊断、工业酶、药物筛选、结晶/结构研究)用途的分子。英国在开发治疗性蛋白质(生物制药)的商业规模生产(生物加工)方面尤其具有创新性，这些蛋白质有可能治疗其他难以治疗的疾病。该地区还在英国直接雇佣了大量劳动力，并对英国产生了直接的社会和经济影响。然而，如果要完全实现返回英国的潜力，这种生物制品的持续开发和商业化需要进一步的变革创新。生物加工展现了一个经济成功的故事，预计到2020年，生物制药的销售额将达到3200亿美元。这些分子在医疗保健中的经济价值和日益增长的重要性显著增加了医疗成本，特别是在生物制药方面，人们面临着更高效、更可预测、更负担得起地设计、开发和制造生物制药的压力。这项提议旨在建立一个充满活力的学术主导的英国专业知识网络(BioProNET)，将学者、工业家和其他感兴趣的团体聚集在一起，整合从事治疗用途生物制剂生产(生物加工)以及非治疗用途生物制剂生产(生物加工)的从业者的专业知识。该网络将侧重于支持功能性生物制品的开发、工程、制造和监测的生物过程，以解决设计更复杂的分子的生产问题。包括生命科学家、生化工程师、化学家、物理学家、数学家、计算科学家和社会科学家在内的多个科学学科的观点和观点将应用于生物制剂制造中生物过程的研究挑战，生物制剂既包括治疗用途的产品(例如生物制药)，也包括非治疗用途的产品(例如生物传感器、药物开发和筛选、诊断)。在该网络中，我们将考虑该地区的发展对社会、环境和经济的影响，以及是否可以改善生物制剂制造的可持续性。该网络将保持英国生物加工行业的国际领先地位(通过利用不同社区持有的广泛知识，这些知识将被聚集在一起，开发和扩展到今天的系统，并扩展到未来25年在世界舞台上竞争所需的系统)，同时为下一代生物制剂的生产建立变革性和创新性的解决方案。通过提高生物加工的成本效益，该部门将转向更负担得起的生物制品/生物制药，以实现可持续和更健康的生活方式。

Biologics are complex molecules made by cellular processes and such biological products have major economic and social value for the UK and globally. Biologics encompass a range of molecules of therapeutic (e.g. biopharmaceutical molecules such as insulin and antibodies like Herceptin) and non-therapeutic (e.g. diagnostics, industrial enzymes, drug screening, crystallization / structural studies) use. The UK has been especially innovative in developing processes for commercial scale production (bioprocessing) of therapeutic proteins (biopharmaceuticals) in particular, that have the potential to treat otherwise intractable diseases. The area also directly employs a large work force in the UK and has direct social and economic impacts on the UK. However, the continued development and commercialization of such biologics requires further step-changing innovation if the full potential return to the UK is to be realised. Bioprocessing presents an economic success story and sales of biopharmaceuticals are estimated to be >$320B by 2020. The economic value and ever-increasing importance of these molecules in healthcare adds significantly to healthcare costs and, in the case of biopharmaceuticals in particular, there is pressure to design, develop and manufacture biopharmaceuticals more efficiently, predictably, and affordably. This proposal sets out to develop a vibrant academic-led UK network (BioProNET) of expertise that will bring together academics, industrialists and other interested groups to integrate the expertise of practitioners working on production (bioprocessing) of biologics of therapeutic use as well as those of non-therapeutic use. The Network will focus on biological processes that underpin the development, engineering, manufacturing and monitoring of functionally active biologics to address production of molecules of greater design complexity. The vision and perspectives of multiple scientific disciplines, including life scientists, biochemical engineers, chemists, physicists, mathematicians, computational scientists, and social scientists will be applied to the research challenges of biological process in the manufacture of biologics, both products of therapeutic use (e.g. biopharmaceuticals) and those of non-therapeutic use (e.g. biosensors, drug development and screening, diagnostics). Within the network we will consider the social, environmental and economic implications of development of the area and whether the sustainability of manufacturing of biologics can be improved. The Network shall maintain the UK bioprocessing sector (by harnessing the breadth of knowledge held in the different communities that will be brought together to develop and extend beyond today's systems into those that will be needed to compete on the world stage over the next 25 years) at the international forefront, whilst establishing step-changing and innovative solutions for the production of the next generation of biologics. By enhancing cost effectiveness of bioprocessing, the sector will move towards more affordable biologics/biopharmaceuticals for sustainable and healthier lifestyles.